Q-omics provides the consensus-scored TARID profile across patient tissues and cancer cell-line models. TARID expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, TARID is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, TARID RNA expression shows 15,558 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LUAD, KIRC, and THYM as cancer lineages where TARID shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TARID — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TARID survival associations across molecular data types. TARID RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TARID RNA expression–survival associations across cancer types. High TARID expression shows unfavorable associations in LUAD, LGG, KIRP, UCEC and CESC, but favorable associations in LIHC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify LUAD as the clearest survival context for TARID RNA expression.
This table summarizes TARID tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TARID. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TARID shows lower tumor expression in KIRC, COAD, KICH, KIRP, BLCA and LUSC. The KIRC box plot shows higher TARID RNA expression in normal versus tumor tissue (log2 FC = −0.731, t-test p < 0.001).
This table shows molecular features associated with TARID in patient tissues and cancer cell lines. In patient samples, TARID shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
